The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination with Yervoy ® (ipilimumab) for the first-line treatment of adult patients with unresectable or metastatic ...

After proper training on subcutaneous injection technique, the prefilled syringe may be administered by the patient or caregiver.

HealthDay News — Among US adults without diabetes, the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) increased from 2018 to 2022, reaching annual prevalence of 0.4% in 2022, according ...

HealthDay News — Bausch + Lomb has announced a voluntary recall of intraocular lenses on its enVista platform due to the potential for an acute postoperative inflammatory reaction.

Uplizna gains new indication; Vanrafia approved for proteinuria in IgAN; Erzofri now available for schizophrenia; setmelanotide shows promise in hypothalamic obesity; GLP-1RAs may reduce dementia risk ...

Seventy-four percent of respondents unaware of FDA-approved treatments; 56% said these options had not been discussed by clinician.

Relevant risk for interaction seen with cardiac implantable electronic devices; no signs of cardiac damage seen during testing.

HealthDay News — Prescribing medical cannabis to patients with chronic health conditions may improve health-related quality of life (HRQL), as well as some specific symptoms such as pain, fatigue, ...

Patients carrying 2 copies of the APOE4 gene (APOE4/4 homozygotes) are more likely to develop AD earlier in life than those without APOE4.

The Dexcom G7 15 Day CGM system is a wearable sensor that continuously measures glucose levels and transmits readings every 5 minutes with no fingersticks or scanning required.

Icotrokinra appears to be an effective treatment for adolescent patients with moderate to severe plaque psoriasis, according to a subgroup analysis of the ICONIC-LEAD study.

The TRANSCEND trial evaluated the efficacy and safety of setmelanotide for the treatment of acquired hypothalamic obesity.